Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.
| dc.contributor.author | Gurney, H | |
| dc.contributor.author | De Campos, E S | |
| dc.contributor.author | Dodwell, David J | |
| dc.contributor.author | Kamthan, A | |
| dc.contributor.author | Thatcher, Nick | |
| dc.date.accessioned | 2010-07-16T15:22:34Z | |
| dc.date.available | 2010-07-16T15:22:34Z | |
| dc.date.issued | 1991 | |
| dc.identifier.citation | Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. 1991, 27 (5):565-8 Eur. J. Cancer | en |
| dc.identifier.issn | 0959-8049 | |
| dc.identifier.pmid | 1647182 | |
| dc.identifier.doi | 10.1016/0277-5379(91)90218-3 | |
| dc.identifier.uri | http://hdl.handle.net/10541/107810 | |
| dc.description.abstract | 42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10/42 patients (23.8%) and stable disease in 25/42 (59.5%). The Karnofsky performance status (KP) improved in 10/42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity. | |
| dc.language.iso | en | en |
| dc.subject | Lung Cancer | en |
| dc.subject | Cancer Metastasis | en |
| dc.subject.mesh | Adenocarcinoma | |
| dc.subject.mesh | Adolescent | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
| dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Ifosfamide | |
| dc.subject.mesh | Lung Neoplasms | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Mitomycins | |
| dc.subject.mesh | Neoplasm Metastasis | |
| dc.subject.mesh | Prognosis | |
| dc.title | Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K. | en |
| dc.identifier.journal | European Journal of Cancer | en |
| html.description.abstract | 42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10/42 patients (23.8%) and stable disease in 25/42 (59.5%). The Karnofsky performance status (KP) improved in 10/42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity. |